Clinical Trials Logo

HER2+ Breast Cancer clinical trials

View clinical trials related to HER2+ Breast Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03632941 Active, not recruiting - Breast Cancer Clinical Trials

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

In this phase II study, study subjects will receive the VRP-HER2 immunizations plus pembrolizumab. There will be an initial Safety Arm during which subjects will receive the VRP-HER2 immunizations plus pembrolizumab. If there is no dose limiting toxicity in the Safety Arm, then subjects will be randomized into 3 arms. They will undergo a biopsy of their tumor and peripheral blood draw for immune cell analyses and be assigned to the applicable arm of the study. Arm A will consist of the the VRP-HER2 immunizations; Arm B will consist of pembrolizumab; Arm C will consist of the VRP-HER2 immunizations plus pembrolizumab.